非小细胞肺癌中的MET改变:当前观点与未来挑战
本文为叙述性综述,总结MET作为非小细胞肺癌致癌驱动因素的作用,讨论MET外显子14跳跃突变、基因扩增与蛋白过表达的检测方法,并回顾MET改变非小细胞肺癌靶向治疗的现有数据与在研临床试验,同时评述免疫治疗数据及未来挑战。
要点
- MET外显子14跳跃突变已有抗MET靶向治疗获批,多种其他药物在研发中。
- MET扩增是致癌基因成瘾非小细胞肺癌常见的旁路耐药机制之一。
- 综述讨论MET外显子14跳跃突变、基因扩增与蛋白过表达的检测方法。
核心结论
- 综述总结MET作为非小细胞肺癌致癌驱动因素的作用,并讨论MET改变非小细胞肺癌靶向治疗的现有数据与未来挑战。
研究设计与样本
- 叙述性综述,检索范围未在原文摘要中具体报告,汇总MET改变非小细胞肺癌的检测方法与靶向治疗、免疫治疗数据。
主要发现
- MET外显子14跳跃突变已有抗MET靶向治疗获批,多种其他药物正在研发中。
- MET扩增是致癌基因成瘾非小细胞肺癌最常见的旁路耐药机制之一。
- 免疫治疗联合或不联合化疗已成为晚期非小细胞肺癌的标准治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted therapies have revolutionized the treatment and improved the outcome for oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have become available. For MET-dysregulated NSCLC (especially MET exon 14 skipping mutations and MET-amplifications, which is one of the most common bypass mechanisms of resistance in oncogene-addicted NSCLC), several anti-MET-targeted therapies have been approved recently (MET exon 14 skipping mutation) and multiple others are in development. In this narrative review, we summarize the role of MET as an oncogenic driver in NSCLC, discuss the different testing methods for exon 14 skipping mutations, gene amplification, and protein overexpression, and review the existing data and ongoing clinical trials regarding targeted therapies in MET-altered NSCLC. As immunotherapy with or without chemotherapy has become the standard of care for advanced NSCLC, immunotherapy data for MET-dysregulated NSCLC are put into perspective. Finally, we discuss future challenges in this rapidly evolving landscape.
引用
- Remon J, Hendriks LEL, Mountzios G, et al. MET alterations in NSCLC-Current Perspectives and Future Challenges. J Thorac Oncol. 2022. PMID: 36441095. doi:10.1016/j.jtho.2022.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。